Intracellular Th (ITCI)

NASDAQ
Currency in USD
131.87
0.00(0.00%)
Closed·
Showing Intracellular Th historical data. For real-time data please try another search
Day's Range
131.63131.98
52 wk Range
64.09131.98
Key Statistics
Edit
Prev. Close
131.87
Open
131.9
Day's Range
131.63-131.98
52 wk Range
64.09-131.98
Volume
-
Average Vol. (3m)
2.84M
1-Year Change
98.69%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
Show more

Intracellular Th Company Profile

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.

Employees
860

Intracellular Th SWOT Analysis


Market Dynamics
Learn about ITCI's commercial strategy, financial performance, and analyst perspectives, with price targets ranging from $132 to $135 pre-acquisition
Pipeline Expansion
Discover ITCI's strategic pipeline developments, including long-acting injectables and new compounds, aimed at broadening its psychiatric treatment offerings
CAPLYTA's Potential
Delve into CAPLYTA's market performance and its $5 billion potential as a first-choice treatment for mood disorders, driving ITCI's financial success
J&J Acquisition
Explore how Johnson & Johnson's acquisition of Intra-Cellular Therapies reshapes the psychiatric drug landscape, potentially accelerating growth and market reach
Read full SWOT analysis

Intracellular Th Earnings Call Summary for Q1/2024

  • CAPLYTA sales surged 53% YoY to $144.8M in Q1 2024; full-year guidance maintained at $645M-$675M
  • Positive results for Lumateperone in MDD; FDA filing planned for H2 2024
  • Strong cash position of $477.4M after $575M public offering; expanding sales force and product portfolio
  • Ongoing clinical programs for Alzheimer's, Parkinson's, and autism spectrum disorders
  • Growing CAPLYTA prescriber base and improved Medicare Part D access support continued growth outlook
Last Updated: 05/07/2024, 04:03 PM
Read Full Transcript

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-- / -0.0528
Revenue / Forecast
-- / 205.96M
EPS Revisions
Last 90 days

People Also Watch

464.39
GEV
+1.21%
104.50
BSX
0.00%
152.75
CAH
+0.17%
716.09
MCK
+0.77%
271.04
TRV
-0.01%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.